Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial by John Haanen, Marco Donia, Inge Marie Svane, Bastiaan Nuijen, Cynthia Nijenhuis, Valesca P Retèl, Tine Monberg, Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Melanie Lindenberg, Wim van Harten

Get full text

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up by Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher

Get full text